Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2278276-46-1
Molecular formula
C6412H9866N1710O2026S44
Molecular weight
144736.04 g/mol
Drug class
Fully human monoclonal IgG4 antibodymyostatin-pathway inhibitor
Mechanism of action
Binds promyostatin and latent myostatin and inhibits activation of myostatin, blocking myostatin signalling involved in limiting skeletal-muscle growth.
Indications / reported uses
Treatment of spinal muscular atrophy (SMA) in adults and paediatric patients aged 2 years and older who are currently receiving an SMN2-targeted treatment under the US FDA Isembyld indication (approval 11 Sep 2026)
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Apitegromab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Apitegromab Permitted Daily Exposure (PDE) report (the Apitegromab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Apitegromab Occupational Exposure Limit (OEL) report (the Apitegromab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.